￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

News

Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Post-treatment of olaparib (olaparib, Lipadro) resistance in ovarian cancer

2026-02-01 22:25:32

Check Details
What is the therapeutic effect of Lynparza (Olaparib, Lipadro) for recurrent ovarian cancer?

2026-02-01 22:25:32

Check Details
Indications for olaparib (Olaparib, Lipadro) for chemotherapy maintenance treatment of ovarian cancer

2026-02-01 22:25:32

Check Details
Efficacy of Lynparza (Olaparib, Lipadro) in the treatment of platinum-sensitive cases in patients with recurrent epithelial ovarian cancer

2026-02-01 22:25:32

Check Details
Olaparib (Olaparib, Lipadro) treatment indications for ovarian cancer

2026-02-01 22:25:32

Check Details
Xolremdi approved, bringing new treatment option to patients with WHIM syndrome

2026-02-01 22:25:32

Check Details
FDA approves Xolremdi to treat rare immune disease WHIM syndrome

2026-02-01 22:25:32

Check Details
FDA officially approves Xolremdi, opening a new chapter in the treatment of rare immune disease WHIM syndrome

2026-02-01 22:25:32

Check Details
Xolremdi (Mavorixafor): Effective treatment for WHIM syndrome

2026-02-01 22:25:32

Check Details
Mavorixafor (Xolremdi) drug introduction

2026-02-01 22:25:32

Check Details
How long do I need to take Valganciclovir?

2026-02-01 22:25:32

Check Details
What are the indications for Valganciclovir?

2026-02-01 22:25:32

Check Details
Category
相关知识